Worldwide Corporate Headquarters
929 North Front Street
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.
439 articles with PPD
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021.
PPD, Inc. will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results.
Aethlon Medical, Inc., a company developing medical technology to treat cancer and life-threatening infectious disease, announced that it has entered into an agreement with PPD, Inc., a leading global contract research organization, for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.
PPD, Inc. (Nasdaq: PPD ) has been recognized with two global excellence awards for its effective learning programs, honoring the company’s high-performing employee development initiatives supporting delivery of global operational excellence and innovative solutions to customers.
PPD, Inc.PPD, Inc., a leading global contract research organization, reported its financial results for the second quarter ended June 30, 2021.
PPD, Inc. will host a conference call on Thursday, July 29, 2021, at 7 a.m. (U.S. Eastern Time) to discuss its second quarter 2021 financial results.
PPD, Inc. (Nasdaq: PPD ) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal , recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic.
PPD, Inc., a leading global contract research organization, held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies.
PPD, Inc. has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Science Leader magazines.
PPD, Inc. was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence Awards during the 2021 World Vaccine Congress.
PPD, Inc., a leading global contract research organization, is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation’s portfolio of services.
PPD, Inc., a leading global contract research organization, reported its financial results for the first quarter ended March 31, 2021.
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced an innovative collaboration in which PPD will be fully enabled to design, build, test, implement and execute digital trials using Science 37's DCT SaaS-based technology platform.
Further expands service offering to pharma and biotech customers - Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry - Adds highly complementary services for the company's fastest growing end market
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated ColitisPhase 1b/2a Study Expected to Begin In 2Q 2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 1b/2a clinical trial
PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, April 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its first quarter 2021 financial results.
PPD Named a Leader in Digital Clinical Trial Solutions by ISG Recognized for comprehensive strengths in the design, deployment of decentralized solutions
Rare Disease Day takes place on the last day of February because it is a month known for having a “rare” number of days.
PPD, Inc. (Nasdaq: PPD ), a leading global contract research organization, will present virtually at the Barclays Global Healthcare Conference. David Simmons, chairman and CEO, and Chris Scully, CFO, are scheduled to participate in a fireside chat on Tuesday, March 9, 2021, at 3:35 p.m. (U.S. Eastern Time).
PPD, Inc., a leading global contract research organization, reported its financial results for the fourth quarter and full year ended December 31, 2020.